Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy

Biomaterials

Volumn 32, Issue 29, 2011, Pages 7139-7150

  Ling, You ^a,b   Wei, Kun ^a,b   Luo, Yun ^c   Gao, Xin ^c   Zhong, Shizhen ^a  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b National Engineering Research Center for Human Tissue Restoration   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antibody; Docetaxel; Magnetic resonance imaging; Prostate cancer; Superparamagnetic iron oxide; Theragnostics

Indexed keywords

ANTICANCER DRUG; ANTIPROLIFERATIVE EFFECT; CANCER THERAPY; CELL LINES; CELLULAR UPTAKE; CLUSTERING EFFECT; CONFOCAL LASER SCANNING MICROSCOPY; CYTOTOXICITY ASSAYS; DOCETAXEL; DRUG ENCAPSULATION; DRUG RELEASE PATTERNS; EVAPORATION METHOD; IN-VITRO; MULTIFUNCTIONAL POLYMER; POLY LACTIC-CO-GLYCOLIC ACID; POLYMER NANOPARTICLES; POLYMER VESICLE; PROSTATE CANCERS; PRUSSIAN BLUE; REAL TIME MONITORING; SINGLE CHAINS; SUPERPARAMAGNETIC BEHAVIOR; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDES; THERAGNOSTICS; THERAPEUTIC EFFECTS; ULTRASENSITIVE;

ANTIBODIES; CELL CULTURE; CONFOCAL MICROSCOPY; CONJUGATED POLYMERS; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; EMULSIFICATION; ENCAPSULATION; ETHYLENE; FUNCTIONAL POLYMERS; GLYCOLS; IRON; MAGNETIC RESONANCE IMAGING; NANOMAGNETICS; NANOPARTICLES; ONCOLOGY; POLYETHYLENE GLYCOLS; RESONANCE; STEM CELLS; SUPERPARAMAGNETISM; TUMORS; X RAY DIFFRACTION;

IRON OXIDES;

ANTIBODY; DOCETAXEL; FERRIC FERROCYANIDE; MACROGOL; POLYLACTIC ACID; PROSTATE STEM CELL ANTIGEN ANTIBODY; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG RELEASE; DRUG TARGETING; DRUG UPTAKE; EMULSION; EVAPORATION; HUMAN; HUMAN CELL; MAGNETISM; MALE; NANOENCAPSULATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PRIORITY JOURNAL; VIBRATION; X RAY DIFFRACTION;

CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLUORESCENT DYES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MATERIALS TESTING; NEOPLASMS; PARTICLE SIZE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TAXOIDS; X-RAY DIFFRACTION;

EID: 79960847763     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.05.089     Document Type: Article

References (45)

1. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer 2008, 8:94-107.
2. Han Z., Fu A., Wang H., Diaz R., Geng L., Onishko H., et al. Noninvasive assessment of cancer response to therapy. Nat Med 2008, 14:343-349.
3. Wang Y.X.J., Hussain S.M., Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331.
4. Bharali D.J., Mousa S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol Therapeut 2010, 128:324-335.
5. Arbab A.S., Yocum G.T., Rad A.M., Khakoo A.Y., Fellowes V., Read E.J., et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. Nmr Biomed 2005, 18:553-559.
6. Corti M., Lascialfari A., Marinone M., Masotti A., Micotti E., Orsini F., et al. Magnetic and relaxometric properties of polyethylenimine-coated superparamagnetic MRI contrast agents. J Magn Magn Mater 2008, 320:316-319.
7. Hsiao J.K., Tai M.F., Lee Y.C., Yang C.Y., Wang H.Y., Liu H.M., et al. Labelling of cultured macrophages with novel magnetic nanoparticles. J Magn Magn Mater 2006, 304:4-6.
8. Lu J., Ma S., Sun J., Xia C., Liu C., Wang Z., et al. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging. Biomaterials 2009, 30:2919-2928.
9. Tsai Z.T., Wang J.F., Kuo H.Y., Shen C.R., Wang J.J., Yen T.C. In situ preparation of high relaxivity iron oxide nanoparticles by coating with chitosan: a potential MRI contrast agent useful for cell tracking. J Magn Magn Mater 2010, 322:208-213.
10. Talelli M., Rijcken C.J.F., Lammers T., Seevinck P.R., Storm G., van Nostrum C.F., et al. Superparamagnetic iron oxide nanoparticles encapsulated in biodegradable thermosensitive polymeric micelles: toward a targeted nanomedicine suitable for image-guided drug delivery. Langmuir 2009, 25:2060-2067.
11. Wente M.N., Jain A., Kono E., Berberat P.O., Giese T., Reber H.A., et al. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas 2005, 31:119-125.
12. Lam J.S., Yamashiro J., Shintaku I.P., Vessella R.L., Jenkins R.B., Horvath S., et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005, 11:2591-2596.
13. Zhigang Z., Wenlv S. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World J Surg Oncol 2004, 2:13-19.
14. Dannull J., Diener P.A., Prikler L., Furstenberger G., Cerny T., Schmid U., et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000, 60:5522-5528.
15. Olafsen T., Gu Z., Sherman M.A., Leyton J.V., Witkosky M.E., Shively J.E., et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007, 30:396-405.
16. Vigor K.L., Kyrtatos P.G., Minogue S., Al-Jamal K.T., Kogelberg H., Tolner B., et al. Nanoparticles functionalised with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells. Biomaterials 2010, 31:1307-1315.
17. Sun S.H., Zeng H., Robinson D.B., Raoux S., Rice P.M., Wang S.X., et al. Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc 2004, 126:273-279.
18. Astete C.E., Kumar C.S.S.R., Sabliov C.M. Size control of poly(d, l-lactide-co-glycolide) and poly(d, l-lactide-co-glycolide)-magnetite nanoparticles synthesized by emulsion evaporation technique. Colloids Surf A 2007, 299:209-216.
19. Chen G., Chen W., Wu Z., Yuan R., Li H., Gao J., et al. MRI-visible polymeric vector bearing CD3 single chain antibody for gene delivery to T cells for immunosuppression. Biomaterials 2009, 30:1962-1970.
20. Kocbek P., Obermajer N., Cegnar M., Kos J., Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007, 120(1-2):18-26.
21. Feng S.-S., Mei L., Anitha P., Gan C.W., Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 2009, 30:3297-3306.
22. Yin Y.-M., Cui F.-D., Mu C.-F., Choi M.-K., Kim J.S., Chung S.-J., et al. Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation. J Control Release 2009, 140:86-94.
23. van Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharmaceut Res 2007, 24:1405-1414.
24. Cornell R.M., Schwertmann U. The iron oxides: structure, properties, reactions, occurrence and uses 1996, VCH, New York, 167-9.
25. Yoon M., Kim Y.M., Kim Y., Volkov V., Song H.J., Park Y.J., et al. Magnetic properties of iron nanoparticles in a polymer film. J Magn Magn Mater 2003, 265:357-362.
26. Liu X., Kaminski M.D., Guan Y., Chen H., Liu H., Rosengart A.J. Preparation and characterization of hydrophobic superparamagnetic magnetite gel. J Magn Magn Mater 2006, 306:248-253.
27. Wei S., Zhu Y., Zhang Y., Xu J. Preparation and characterization of hyperbranched aromatic polyamides/Fe3O4 magnetic nanocomposite. Reac Funct Polym 2006, 66:1272-1277.
28. Jain T.K., Morales M.A., Sahoo S.K., Leslie-Pelecky D.L., Labhasetwar V. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharmaceutics 2005, 2:194-205.
29. Thanki Paragkumar N., Dellacherie Edith, Six Jean-Luc Surface characteristics of PLA and PLGA films. Appl Surf Sci 2006, 253:2758-2764.
30. Kiss É, Bertóti I. Vargha-Butler EI. XPS and wettability characterization of modified poly(lactic acid) and poly(lactic/glycolic acid) films. J Colloid Interface Sci 2002, 245:91-98.
31. Wen X.Q., Li X.J., Liao B., Liu Y., Wu J.Y., Yuan X.X., et al. Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel. Urology 2009, 73:1407-1411.
32. Luo Y., Ling Y., Guo W.S., Pang J., Liu W.P., Fang Y.Q., et al. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J Control Release 2010, 147:278-288.
33. Win K.Y., Feng S.S. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005, 26:2713-2722.
34. Dilnawaz F., Singh A., Mohanty C., Sahoo S.K. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 2010, 31:3694-3706.
35. Musumeci T., Ventura C.A., Giannone I., Ruozi B., Montenegro L., Pignatello R., et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 2006, 325:172-179.
36. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
37. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers-advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992, 3:351-362.
38. ® liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. BBA-Biomembranes 2003, 1609:102-108.
39. Danhier F., Feron O., Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148:135-146.
40. Kateb B., Chiu K., Black K.L., Yamamoto V., Khalsa B., Ljubimova J.Y., et al. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy?. Neuroimage 2011, 54:106-124.
41. Jin Hee M., Don-Haeng L., Kyung Hee J., You-Han B., In-Suh P., Seok J., et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 2010, 4995-5006.
42. Yang X., Grailer J.J., Rowland I.J., Javadi A., Hurley S.A., Steeber D.A., et al. Multifunctional SPIO/DOX-loaded wormlike polymer vesicles for cancer therapy and MR imaging. Biomaterials 2010, 31:9065-9073.
43. Wang P.C., Lee C.F., Young T.H., Lin D.T., Chiu W.Y. Preparation and clinical application of immunomagnetic latex. J Polym Sci Part A Polym Chem 2005, 43:1342-1356.
44. Hu F.X., Neoh K.G., Kang E.T. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials 2006, 27:5725-5733.
45. Hamoudeh M., Al Faraj A., Canet-Soulas E., Bessueille F., Leonard D., Fessi H. Elaboration of PLLA-based superparamagnetic nanoparticles: characterization, magnetic behavior study and in vitro relaxivity evaluation. Int J Pharm 2007, 338:248-257.